中医疗法在治疗间质性肺纤维化疾病中的研究进展
Research Progress of Traditional Chinese Medicine in the Treatment of Interstitial Pulmonary Fibrosis Disease
摘要: 间质性肺纤维化(Interstitial Pulmonary Fibrosis, IPF)是一种发生在肺部的以弥漫性肺泡炎症、细胞结构紊乱及间质纤维化为特征的慢性、进展性、不可逆的间质性疾病。然而现代医学治疗肺纤维化的手段十分有限，近些年来中医药在改善肺纤维化疾病的临床症状、延缓纤维化进展等方面展现出独特优势，研究显示，中药复方或中医艾灸联合西药(吡非尼酮、尼达尼布)可显著改善患者肺功能，延缓纤维化的进展，且具有良好的安全性。本文结合了近年来国内外关于中医药治疗间质性肺纤维化疾病的研究，探讨从中医病名归属、中医药治疗间质性肺纤维化的理论基础、作用机制及临床疗效的研究进展，以期可以为IPF的治疗提供新的思路和方向。
Abstract: Interstitial pulmonary fibrosis (IPF) is a chronic, progressive and irreversible interstitial lung disease characterized by diffuse alveolar inflammation, cellular structural disorder and interstitial fibrosis. However, modern medical treatment options for pulmonary fibrosis are quite limited. In recent years, traditional Chinese medicine has demonstrated unique advantages in improving clinical symptoms of pulmonary fibrosis and delaying the progression of fibrosis. Studies have shown that traditional Chinese medicine formulas or the combination of traditional Chinese medicine moxibustion and Western medicine (pirfenidone, nintedanib) can significantly improve lung function in patients, delay the progression of fibrosis, and have good safety. This article combines domestic and international research on the treatment of interstitial pulmonary fibrosis with traditional Chinese medicine in recent years, and explores the research progress in the classification of traditional Chinese medicine disease names, theoretical basis, mechanism of action and clinical efficacy of traditional Chinese medicine in the treatment of interstitial pulmonary fibrosis, with the aim of providing new ideas and directions for the treatment of IPF.
文章引用：刘兆云, 王星昊, 李建英. 中医疗法在治疗间质性肺纤维化疾病中的研究进展[J]. 临床医学进展, 2025, 15(8): 137-143. https://doi.org/10.12677/acm.2025.1582210

参考文献

[1] Koudstaal, T. and Wijsenbeek, M.S. (2023) Idiopathic Pulmonary Fibrosis. La Presse Médicale, 52, Article 104166. [Google Scholar] [CrossRef] [PubMed]
[2] Maher, T.M., Bendstrup, E., Dron, L., Langley, J., Smith, G., Khalid, J.M., et al. (2021) Global Incidence and Prevalence of Idiopathic Pulmonary Fibrosis. Respiratory Research, 22, Article No. 197. [Google Scholar] [CrossRef] [PubMed]
[3] Salton, F., Volpe, M. and Confalonieri, M. (2019) Epithelial-Mesenchymal Transition in the Pathogenesis of Idiopathic Pulmonary Fibrosis. Medicina, 55, Article 83. [Google Scholar] [CrossRef] [PubMed]
[4] Ley, B., Collard, H.R. and King, T.E. (2011) Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 183, 431-440. [Google Scholar] [CrossRef] [PubMed]
[5] Noble, P.W., Barkauskas, C.E. and Jiang, D. (2012) Pulmonary Fibrosis: Patterns and Perpetrators. Journal of Clinical Investigation, 122, 2756-2762. [Google Scholar] [CrossRef] [PubMed]
[6] Koudstaal, T., Funke-Chambour, M., Kreuter, M., Molyneaux, P.L. and Wijsenbeek, M.S. (2023) Pulmonary Fibrosis: From Pathogenesis to Clinical Decision-Making. Trends in Molecular Medicine, 29, 1076-1087. [Google Scholar] [CrossRef] [PubMed]
[7] 曾梓苑, 陈生, 黄俊浩, 等. 国医大师晁恩祥运用养阴益气法治疗肺痿经验[J]. 陕西中医, 2022, 43(10): 1442-1444+1448.
[8] 世界中医药学会联合会内科专业委员会. 特发性肺纤维化中医诊疗指南[J]. 中国循证医学杂志, 2025, 25(3): 249-255.
[9] 马君. 关于肺纤维化中医命名的思考[J]. 现代中西医结合杂志, 2007(13): 1763+1773.
[10] 杨淦, 张先元, 曹栀, 等. 特发性肺纤维化与肺痹、肺萎关系浅析[J]. 亚太传统医药, 2015, 11(2): 52-53.
[11] 张志超, 周贤梅. 特发性肺纤维化的中医治疗研究进展[J]. 大医生, 2025, 10(7): 132-136.
[12] 任娟宁, 范文京, 李彤, 等. 麦门冬汤化学成分及治疗肺纤维化研究进展[J]. 辽宁中医药大学学报, 2022, 24(6): 155-159.
[13] 牛情园, 黄丽萍, 刘红宁. 麦冬本草考证、化学成分、药理作用及临床应用研究进展[J/OL]. 中华中医药学刊, 1-15.
http://kns.cnki.net/kcms/detail/21.1546.R.20250511.1135.002.html, 2025-05-28.
[14] Lao, Q., Wang, X., Zhu, G., Yuan, H., Ma, T. and Wang, N. (2024) A Chinese Classical Prescription Maimendong Decoction in Treatment of Pulmonary Fibrosis: An Overview. Frontiers in Pharmacology, 15, Article ID: 1329743. [Google Scholar] [CrossRef] [PubMed]
[15] Zhou, Y., Su, W., Xu, M., Zhang, A., Li, S., Guo, H., et al. (2025) Maimendong Decoction Modulates the PINK1/Parkin Signaling Pathway Alleviates Type 2 Alveolar Epithelial Cells Senescence and Enhances Mitochondrial Autophagy to Offer Potential Therapeutic Effects for Idiopathic Pulmonary Fibrosis. Journal of Ethnopharmacology, 345, Article 119568. [Google Scholar] [CrossRef] [PubMed]
[16] Shuangshuang, H., Mengmeng, S., Lan, Z., Fang, Z. and Yu, L. (2024) Corrigendum to “Maimendong Decoction Regulates M2 Macrophage Polarization to Suppress Pulmonary Fibrosis via PI3K/Akt/FOXO3a Signalling Pathway-Mediated Fibroblast Activation” [J. Ethnopharmacol. 319 117308]. Journal of Ethnopharmacology, 323, Article 117719. [Google Scholar] [CrossRef] [PubMed]
[17] 辛亚然, 谭绍坤, 李明伟, 等. 血府逐瘀汤在改善心脑血管疾病中的研究进展[J]. 长春中医药大学学报, 2025, 41(5): 581-585.
[18] 于宁霞, 李宣霖, 余学庆, 等. 补肺活血法治疗肺纤维化的Meta分析[J]. 中医研究, 2019, 32(11): 68-72.
[19] 武运邦, 谢红, 王金义, 等. 血府逐瘀汤对肺纤维化大鼠肺组织上皮间质转化的影响及其机制研究[J]. 中国民族民间医药, 2020, 294(17): 11-16.
[20] 丁大力, 沈学彬, 姚佳慧, 等. 中药治疗肺纤维化的研究进展[J]. 中草药, 2021, 52(22): 7006-7024.
[21] 付慧婕, 雷根平, 董盛, 等. 黄芪的现代药理作用及研究进展[J]. 河北中医, 2025, 47(4): 695-699+704.
[22] 袁速. 黄芪甲苷对肺纤维化的作用及机制探究[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2023.
[23] Lin, W., Song, Y., Li, T., Yan, J., Zhang, R., Han, L., et al. (2023) Triptolide Attenuates Pulmonary Fibrosis by Inhibiting Fibrotic Extracellular Matrix Remodeling Mediated by MMPs/LOX/Integrin. Biomedicine & Pharmacotherapy, 166, Article 115394. [Google Scholar] [CrossRef] [PubMed]
[24] 宋倩男, 李淼, 李贵星, 等. 雷公藤甲素改善博来霉素所致肺纤维化模型小鼠肺功能及内质网应激作用机制[J]. 时珍国医国药, 2022, 33(12): 2971-2973.
[25] 朱丽华, 田燕歌, 张蓝熙, 等. 针灸治疗慢性呼吸系统疾病的机制研究进展[J]. 中华中医药杂志, 2020, 35(8): 4059-4062.
[26] 许媛媛, 边渊, 黄虎威, 等. 八段锦联合肺康复训练对稳定期IPF患者肺功能、运动耐力和情绪的影响[J]. 中外医学研究, 2024, 22(35): 27-30.
[27] 范良, 卢保强, 陈荣, 等. 肺部疾病的中医特色技术诊疗运用及机制研究进展[J]. 现代中西医结合杂志, 2021, 30(35): 3983-3986+3990.
[28] 桑娟, 刘凡. 人参皂苷Rb1通过调控Wnt3/β-Catenin通路对结缔组织并发间质性肺炎大鼠肺纤维化的影响[J]. 贵州医科大学学报, 2025, 50(1): 48-56.
[29] 周怡菲, 刘锐, 刘丽, 等. 麦门冬汤对肺纤维化大鼠JAK2/STAT1信号通路的影响[J]. 时珍国医国药, 2024, 35(1): 52-55.
[30] Thannickal, V.J., Toews, G.B., White, E.S., Lynch III, J.P. and Martinez, F.J. (2004) Mechanisms of Pulmonary Fibrosis. Annual Review of Medicine, 55, 395-417. [Google Scholar] [CrossRef] [PubMed]
[31] 吕安淇, 姜成, 左婉曌, 等. 基于NLRP3炎症小体的中医药干预特发性肺纤维化研究进展[J]. 北京中医药, 2025, 44(2): 253-260.
[32] 梁志辉, 杨曙光, 徐莉莉, 等. 中药复方抗氧化应激干预IPF的研究进展[J]. 中国中医急症, 2025, 34(4): 737-740.
[33] 梁媛, 田辉, 黄俊涛, 等. 热敏灸联合肺纤通络方对特发性肺纤维化患者血气分析、呼吸困难程度及氧化应激指标的影响[J]. 河北中医, 2025, 47(5): 830-833+838.
[34] 沈金峰, 黄伟, 晏子友. 肾衰方及其拆方对MMP7、α-SMA调节作用的探讨[J]. 中医药学报, 2018, 46(6): 43-47.
[35] 王祺, 关玉娟, 齐越, 等. 血府逐瘀汤对肺纤维化大鼠肺组织Smad-3、MMP-7蛋白表达的影响[J]. 辽宁中医药大学学报, 2019, 21(9): 36-39.

为你推荐